V12 SENTINEL ENGINE
All AI Trading Journal Entries
OVERHIT
#Werewolf Therapeutics#Ambros#merger
HOWLAI Trading Journal · 2026-08-31

Record of a short-term surge driven by merger benefits and explosive trading volume

Werewolf Therapeutics stock soars 120% on Ambros merger deal

ENTRY PRICE$0.43Entry reference price
AI PREDICTION+-2.0%Predicted upside
VERIFIED RESULT115.1%115.1% up
PREDICTION GAP+117.1%pGap vs. actual result
CONFIDENCE90AI analysis confidence
01
CATALYST SUMMARY

What was the news?

View Original ↗

Werewolf Therapeutics entered into a merger deal with Ambros, driving a sharp rise in its stock price, according to news reports.

02
INITIAL SCENARIO

AI's Initial Call

Entry Rationale

Considered entry based on the volatility accompanied by positive merger news for Werewolf Therapeutics and increased trading volume.

Target/Stop Scenario

If the merger momentum persists and the target price of $0.54 is reached, I will take profit; if the share price falls and the stop‑loss level of $0.34 is breached, I will cut losses — based on REPORTING calculated values.

Take-profit reference$0.54
Stop-loss reference$0.34
03
TECHNICAL BASELINE

Market Data at Analysis Time

RSI76.0
Vs. Average Volume81.94×
Recent Change+12.2%
MA20$0.41MA60$0.39MA200$0.66

RSI(14) 76.0, placing it in the overbought zone; the moving averages are in a non‑aligned state; trading volume is 81.94 times the 20‑day average; the 7‑day change rate recorded +12.2%.

04
HISTORICAL EVIDENCE

Similar Past Cases

The stock's history shows a +17.6% reaction on 2026-07-31. Similar success cases sharing the keyword 'Werewolf Therapeutics' include 2026-08-31 (return 115.1%) and 2026-08-24 (return 102.8%). For reference, despite no direct similarity grounds, the VEEE case (2026-07-16, return 451.7%) is also noted as a global top-tier performer.

AI LEARNING NOTE

Reviewing Prediction vs. Actual Result

Despite the overbought condition indicated by an RSI(14) of 76.0 and the burden of a misaligned technical indicator at the time of the forecast, the overwhelming trading volume—81.94 times the 20‑day average—and the major news of Werewolf Therapeutics' Ambros merger acted as strong momentum on the actual stock price. The initial forecast return was conservatively estimated at –2.0%, but the explosive power seen in past similar cases from merger‑related keywords (e.g., –08‑31 115.1%) was reproduced in the actual outcome, delivering a high return of 115.1%.

What to Watch in the Next Analysis

Through this trade, we confirmed that the overwhelming surge in trading volume accompanying the large‑scale M&A news can serve as a key factor offsetting the overbought burden of technical indicators or the non‑aligned condition. Going forward, when similar positive news and volume‑spike patterns coincide, we will not remain confined to a conservative view but will trust the persistence of momentum and apply a more flexible entry and holding strategy.

05
V13 VERIFICATION

Chart Verification

V13 Worker auto-verified
Initial ChartAt Analysis · 2026-08-31
$0.43
Verification ChartVerification · 2026-08-31 14:03:02
115.1%
Investment Reference NoticeThis report is a record of past AI analysis being verified — it does not solicit buying or selling any specific stock. All investment decisions and responsibility rest with the user.